Table 1.
Baseline characteristics of the EOPC and LOPC groups
| Variable | N | EOPC N = 4523 | LOPC N = 68,383 | P value |
|---|---|---|---|---|
| Age, years (range) | 72,906 | 46 (19–49) | 69 (50–103) | |
| Male gender | 72,906 | 2625 (58.0%) | 35,024 (51.2%) | < 0.001 |
| Tumor location (pancreatic head) | 72,906 | 2301 (50.9%) | 35,512 (51.9%) | 0.168 |
| Tumor size > 2 cm | 57,352 | 3275 (91.5%) | 48,923 (91.0%) | 0.340 |
| AJCC stage 7th edition | 62,146 | < 0.001 | ||
| I | 157 (3.9%) | 3633 (6.3%) | ||
| II | 1039 (25.9%) | 16,966 (29.2%) | ||
| III | 461 (11.5%) | 6020 (10.4%) | ||
| IV | 2359 (58.7%) | 31,511 (54.2%) | ||
| Surgery | 72,092 | 1037 (23.2%) | 13,456 (19.9%) | < 0.001 |
| Radiation therapy (yes vs no*) | 72,279 | 1058 (23.6%) | 11,904 (17.6%) | < 0.001 |
| Chemotherapy (yes vs no*) | 72,906 | 3316 (73.3%) | 37,907 (55.4%) | < 0.001 |
N, number of non-missing values. Qualitative data are expressed as N (%) and quantitative data as median (range). *No evidence of radiotherapy or chemotherapy was found in the medical records examined. EOPC, early-onset pancreatic cancer; LOPC, later-onset pancreatic cancer